Abstract
The KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases represents the first update to this set of recommendations since the initial set of KDIGO guideline recommendations was published in 2012. The pace of growth in our molecular understanding of glomerular disease has quickened and a number of newer immunosuppressive and targeted therapies have been introduced since the original set of guideline recommendations, making such an update necessary. Despite these updates, many areas of controversy remain. In addition, further updates since the publication of KDIGO 2021 have occurred which this guideline does not encompass. With this commentary, the KDOQI work group has generated a chapter-by-chapter companion opinion article that provides commentary specific to the implementation of the KDIGO 2021 guideline in the United States.
Original language | English (US) |
---|---|
Pages (from-to) | 121-175 |
Number of pages | 55 |
Journal | American Journal of Kidney Diseases |
Volume | 82 |
Issue number | 2 |
DOIs | |
State | Published - Aug 2023 |
Bibliographical note
Publisher Copyright:© 2023 National Kidney Foundation, Inc.
Keywords
- CPG
- Commentary
- Glomerular disease
- Glomerulonephritis
- KDIGO 2021
- KDOQI Work Group
- Nephrotic syndrome
PubMed: MeSH publication types
- Journal Article
- Practice Guideline